Navigation Links
Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
Date:9/17/2008

CRANBURY, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), today announced that President and Chief Executive Officer John F. Crowley will make a presentation at the UBS Global Life Sciences Conference on Wednesday, September 24, 2008, at 10:30 a.m. EDT in New York.

An audio webcast of the presentation will be available at the Amicus Web site at http://www.amicustherapeutics.com. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the webcast. An audio replay of the webcast will also be available on the Company's Web site for 30 days until October 24, 2008.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Opens Research Facility in San Diego
2. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
3. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
4. Amicus Therapeutics Announces First Quarter 2008 Financial Results
5. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
7. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
10. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
11. Amicus Therapeutics to Host R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Intralytix, Inc. announced that it received $17.5 million in ... This investment marks the beginning of a close collaboration ... for various benefits in human health and in other ... As a global key player in yeasts ... for baking, food taste & pleasure, health care, and ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health ... announced its full advisory board. The board comprises leaders spanning business, technology, academia, ... PhD, former VP of Engineering, to Chief Technology Officer. Crooks will lead strategy ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):